ProCE Banner Activity

Cases in CLL Slides: Third-line Treatment Following BTK Inhibitor– and Venetoclax-Based Therapy

Slideset Download
Download this slideset for expert perspectives on third-line treatment considerations for patients with CLL requiring new treatment following BTK inhibitor– and venetoclax-based therapy.

Released: October 14, 2020

Expiration: October 13, 2021

No longer available for credit.

Share

Faculty

Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by the USF Health
ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts